title: Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment             of NSCLC.
abstract: Lung cancer is one of the most common tumors and its treatment is still             inefficient. In our previous work we proved that ciprofloxacin has a different             influence on five cancer cell lines. Here, we aimed to compare the biological             effect of ciprofloxacin on cell lines representing different responses after treatment,             thus A549 was chosen as a sensitive model, C6 and B16 as highly resistant. Three             different cell lines were analyzed (A549, B16 and C6). The characterization of             continuous cell growth was analyzed with the Real-Time Cell Analyzer (RTCA)-DP             system. Cytoskeletal changes were demonstrated using immunofluorescence. The cell             cycle was analyzed using flow cytometry. Ciprofloxacin was cytostatic only against             the A549 cell line. In the case of other tested cell lines a cytostatic effect             was not observed. Cytoskeletal analysis confirms the results obtained with RTCA-DP.             A549 cells were inhibited in the G2/M phase suggesting a mechanism related to             topoisomerase II inhibition. The biological effects of ciprofloxacin support the             hypothesis that this drug can serve as an adjuvant treatment for lung cancer,             due to its properties enabling topoisomerase II inhibition.
authors.affiliation: Department of Tissue Engineering, Nicolaus Copernicus University, Bydgoszcz, Poland. tomaszkloskowski@op.pl
authors.forename: Tomasz
authors.initials: T
authors.lastname: Kloskowski
authors.forename: Natalia
authors.initials: N
authors.lastname: Gurtowska
authors.forename: Joanna
authors.initials: J
authors.lastname: Olkowska
authors.forename: Jakub Marcin
authors.initials: JM
authors.lastname: Nowak
authors.forename: Jan
authors.initials: J
authors.lastname: Adamowicz
authors.forename: Jakub
authors.initials: J
authors.lastname: Tworkiewicz
authors.forename: Robert
authors.initials: R
authors.lastname: Dębski
authors.forename: Alina
authors.initials: A
authors.lastname: Grzanka
authors.forename: Tomasz
authors.initials: T
authors.lastname: Drewa
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002939:Ciprofloxacin / Q000494:pharmacology*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D051379:Mice; D051381:Rats; D059005:Topoisomerase II Inhibitors / Q000494:pharmacology*
chemical_list: D000199:Actins; D000970:Antineoplastic Agents; D059005:Topoisomerase II Inhibitors; D002939:Ciprofloxacin; D004250:DNA Topoisomerases, Type II